{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:43:17Z","timestamp":1787312597165,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T00:00:00Z","timestamp":1487030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40265-017-0703-7","type":"journal-article","created":{"date-parts":[[2017,2,13]],"date-time":"2017-02-13T20:20:02Z","timestamp":1487017202000},"page":"345-352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Teduglutide: A Review in Short Bowel Syndrome"],"prefix":"10.1007","volume":"77","author":[{"given":"Esther S.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,14]]},"reference":[{"issue":"1","key":"703_CR1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cgh.2005.10.002","volume":"4","author":"SJD O\u2019Keefe","year":"2006","unstructured":"O\u2019Keefe SJD, Buchman AL, Fishbein TM, et al. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol. 2006;4(1):6\u201310.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"1 Suppl","key":"703_CR2","doi-asserted-by":"crossref","first-page":"8S","DOI":"10.1177\/0148607114520994","volume":"38","author":"PB Jeppesen","year":"2014","unstructured":"Jeppesen PB. Spectrum of short bowel syndrome in adults: intestinal insufficiency to intestinal failure. J Parenter Enter Nutr. 2014;38(1 Suppl):8S\u201313S.","journal-title":"J Parenter Enter Nutr."},{"key":"703_CR3","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. Short bowel syndrome. 2015. https:\/\/www.niddk.nih.gov . Accessed 18 Jan 2017."},{"key":"703_CR4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-3-319-17169-2_43","volume-title":"Textbook of pediatric gastroenterology, hepatology and nutrition: a comprehensive guide to practice","author":"JA Vanderhoof","year":"2016","unstructured":"Vanderhoof JA, Pauley-Hunter R. Short-bowel syndrome. In: Guandalini S, Dhawan A, Branski D, editors. Textbook of pediatric gastroenterology, hepatology and nutrition: a comprehensive guide to practice. Cham: Springer International Publishing; 2016. p. 495\u2013503."},{"issue":"2","key":"703_CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","volume":"35","author":"L Pironi","year":"2016","unstructured":"Pironi L, Arends J, Bozzetti F, et al. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016;35(2):247\u2013307.","journal-title":"Clin Nutr."},{"issue":"1 Suppl","key":"703_CR6","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1177\/0148607113520005","volume":"38","author":"KA Tappenden","year":"2014","unstructured":"Tappenden KA. Pathophysiology of short bowel syndrome: considerations of resected and residual anatomy. J Parenter Enter Nutr. 2014;38(1 Suppl):14S\u201322S.","journal-title":"J Parenter Enter Nutr."},{"issue":"Suppl 1","key":"703_CR7","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.1177\/0148607114525210","volume":"38","author":"KA Tappenden","year":"2014","unstructured":"Tappenden KA. Intestinal adaptation following resection. J Parenter Enter Nutr. 2014;38(Suppl 1):23S\u201331S.","journal-title":"J Parenter Enter Nutr."},{"key":"703_CR8","unstructured":"NPS Pharma Holdings Limited. Revestive (teduglutide) 5 mg powder and solvent for solution for injection: EU summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 31 Jan 2017."},{"issue":"1","key":"703_CR9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.sempedsurg.2009.11.010","volume":"19","author":"ME McMellen","year":"2010","unstructured":"McMellen ME, Wakeman D, Longshore SW, et al. Growth factors: possible roles for clinical management of the short bowel syndrome. Semin Pediatr Surg. 2010;19(1):35\u201343.","journal-title":"Semin Pediatr Surg."},{"issue":"1 Suppl","key":"703_CR10","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1177\/0148607114526241","volume":"38","author":"PB Jeppesen","year":"2014","unstructured":"Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. J Parenter Enter Nutr. 2014;38(1 Suppl):45S\u201352S.","journal-title":"J Parenter Enter Nutr."},{"issue":"4","key":"703_CR11","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0148607113512678","volume":"38","author":"DG Kelly","year":"2014","unstructured":"Kelly DG, Tappenden KA, Winkler MF. Short bowel syndrome: highlights of patient management, quality of life, and survival. J Parenter Enter Nutr. 2014;38(4):427\u201337.","journal-title":"J Parenter Enter Nutr."},{"issue":"9","key":"703_CR12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-013-0070-y","volume":"73","author":"CB Burness","year":"2013","unstructured":"Burness CB, McCormack PL. Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. Drugs. 2013;73(9):935\u201347.","journal-title":"Drugs."},{"issue":"5","key":"703_CR13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40261-015-0286-6","volume":"35","author":"K McKeage","year":"2015","unstructured":"McKeage K. Teduglutide: a guide to its use in short bowel syndrome. Clin Drug Invest. 2015;35(5):335\u201340.","journal-title":"Clin Drug Invest."},{"issue":"9","key":"703_CR14","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/gut.2004.061440","volume":"54","author":"PB Jeppesen","year":"2005","unstructured":"Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224\u201331.","journal-title":"Gut."},{"issue":"7","key":"703_CR15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/MCG.0b013e3182828f57","volume":"47","author":"KA Tappenden","year":"2013","unstructured":"Tappenden KA, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013;47(7):602\u20137.","journal-title":"J Clin Gastroenterol."},{"key":"703_CR16","doi-asserted-by":"publisher","unstructured":"Seidner DL, Joly F, Youssef NN. Effect of teduglutide, a glucagon-like peptide 2 analog, on citrulline levels in patients with short bowel syndrome in two phase III randomized trials. Clin Transl Gastroenterol. 2015. doi: 10.1038\/ctg.2015.15 .","DOI":"10.1038\/ctg.2015.15"},{"key":"703_CR17","doi-asserted-by":"publisher","unstructured":"Carter BA, Cohran VC, Cole CR, et al. Outcomes from a 12-week, open-label, multicenter clinical trial of teduglutide in pediatric short bowel syndrome. J Pediatr. 2016. doi: 10.1016\/j.jpeds.2016.10.027 .","DOI":"10.1016\/j.jpeds.2016.10.027"},{"key":"703_CR18","doi-asserted-by":"publisher","unstructured":"Schwartz LK, O\u2019Keefe SJD, Fujioka K, et al. Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome. Clin Transl Gastroenterol. 2016. doi: 10.1038\/ctg.2015.69 .","DOI":"10.1038\/ctg.2015.69"},{"key":"703_CR19","doi-asserted-by":"crossref","unstructured":"O\u2019Keefe SJD, Jeppesen PB, Gilroy R, et al. Safety and efficacy of teduglutide after 52 weeks of treatment in patients with short bowel intestinal failure. Clin Gastroenterol Hepatol. 2013;11(7):815\u201323.e1-3.","DOI":"10.1016\/j.cgh.2012.12.029"},{"issue":"2","key":"703_CR20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2160763X12438745","volume":"1","author":"M Hartmann","year":"2012","unstructured":"Hartmann M, Timmer W, Schultz A, et al. A thorough QT study of teduglutide in healthy subjects. Clin Pharmacol Drug Dev. 2012;1(2):57\u201366.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"703_CR21","doi-asserted-by":"publisher","unstructured":"Berg JK, Kim EH, Li B, et al. A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects. BMC Gastroenterol. 2014;14:25. doi: 10.1186\/1471-230X-14-25 .","DOI":"10.1186\/1471-230X-14-25"},{"key":"703_CR22","doi-asserted-by":"publisher","unstructured":"Iturrino J, Camilleri M, Acosta A, et al. Acute effects of a glucagon-like peptide 2 analogue, teduglutide, on gastrointestinal motor function and permeability in adult patients with short bowel syndrome on home parenteral nutrition. J Parenter Enter Nutr. 2015. doi: 10.1177\/0148607115597644 .","DOI":"10.1177\/0148607115597644"},{"key":"703_CR23","unstructured":"European Medicines Agency. Revestive-H-C-2345-II-20: EPAR assessment report-variation. 2016. http:\/\/www.ema.europa.eu . Accessed 31 Jan 2017."},{"issue":"5","key":"703_CR24","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00228-012-1455-7","volume":"69","author":"R Nave","year":"2013","unstructured":"Nave R, Halabi A, Herzog R, et al. Pharmacokinetics of teduglutide in subjects with renal impairment. Eur J Clin Pharmacol. 2013;69(5):1149\u201355.","journal-title":"Eur J Clin Pharmacol."},{"key":"703_CR25","unstructured":"European Medicines Agency. Revestive: EPAR-public assessment report. 2012. http:\/\/www.ema.europa.eu . Accessed 31 Jan 2017."},{"issue":"7","key":"703_CR26","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1136\/gut.2010.218271","volume":"60","author":"PB Jeppesen","year":"2011","unstructured":"Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011;60(7):902\u201314.","journal-title":"Gut."},{"key":"703_CR27","doi-asserted-by":"crossref","unstructured":"Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473\u201381.e3.","DOI":"10.1053\/j.gastro.2012.09.007"},{"issue":"1 Suppl","key":"703_CR28","first-page":"A111","volume":"2","author":"K Iyer","year":"2014","unstructured":"Iyer K, Fujioka K, Boullata JI, et al. Safety and efficacy of long-term teduglutide treatment for patients with short bowel syndrome and intestinal failure: final results of the steps-3 study [abstract no. OP350]. United Eur Gastroenterol J. 2014;2(1 Suppl):A111.","journal-title":"United Eur Gastroenterol J."},{"issue":"6 Suppl","key":"703_CR29","first-page":"S27","volume":"99","author":"K Fujioka","year":"2015","unstructured":"Fujioka K, Schneider SM, Li B, et al. Teduglutide, a recombinant analog of GLP-2, reduces parenteral support in patients with short bowel syndrome regardless of ultra-short remnant bowel and\/or no colon-in-continuity anatomy [abstract no. 190]. Transplantation. 2015;99(6 Suppl):S27.","journal-title":"Transplantation."},{"issue":"5","key":"703_CR30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.clnu.2013.03.016","volume":"32","author":"PB Jeppesen","year":"2013","unstructured":"Jeppesen PB, Pertkiewicz M, Forbes A, et al. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide\u2013analyses from a randomised, placebo-controlled study. Clin Nutr. 2013;32(5):713\u201321.","journal-title":"Clin Nutr."},{"key":"703_CR31","doi-asserted-by":"publisher","unstructured":"Iyer KR, Kunecki M, Boullata JI, et al. Independence from parenteral nutrition and intravenous fluid support during treatment with teduglutide among patients with intestinal failure associated with short bowel syndrome. J Parenter Enter Nutr. 2016. doi: 10.1177\/0148607116680791 .","DOI":"10.1177\/0148607116680791"},{"issue":"Suppl 1","key":"703_CR32","doi-asserted-by":"crossref","first-page":"S749","DOI":"10.14309\/00000434-201510001-01763","volume":"110","author":"NN Youssef","year":"2015","unstructured":"Youssef NN, Pape U-F, Delmaestro E, et al. Long-term safety of teduglutide treatment for patients with intestinal failure associated with short bowel syndrome [abstract no. 1763]. Am J Gastroenterol. 2015;110(Suppl 1):S749\u201350.","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 1","key":"703_CR33","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/S0261-5614(14)50173-2","volume":"33","author":"PB Jeppesen","year":"2014","unstructured":"Jeppesen PB, Boullata JI, Ziegler TR, et al. Independence from parenteral support achieved with teduglutide treatment in patients with intestinal failure associated with short bowel syndrome [abstract no. PP131-SUN]. Clin Nutr. 2014;33(Suppl 1):S68\u20139.","journal-title":"Clin Nutr."},{"key":"703_CR34","doi-asserted-by":"publisher","unstructured":"Fujioka K, Jeejeebhoy K, Pape UF, et al. Patients with short bowel on narcotics during 2 randomized trials have abdominal complaints independent of teduglutide. J Parenter Enter Nutr. 2016. doi: 10.1177\/0148607116663481 .","DOI":"10.1177\/0148607116663481"},{"key":"703_CR35","unstructured":"Shire. Shire receives extension of market authorization in Europe for Revestive\u00ae (teduglutide) for the treatment of paediatric patients with short bowel syndrome (SBS) [media release]. 7 July 2016. https:\/\/www.shire.com ."},{"key":"703_CR36","doi-asserted-by":"publisher","unstructured":"Compher C, Boullata JI, Pickett-Blakely O, et al. Clinical management of patients with parenteral nutrition-dependent short bowel syndrome during teduglutide therapy. J Parenter Enter Nutr. 2015. doi: 10.1177\/0148607115594010 .","DOI":"10.1177\/0148607115594010"},{"key":"703_CR37","doi-asserted-by":"publisher","unstructured":"Kochar B, Long MD, Shelton E, et al. Safety and efficacy of teduglutide (Gattex) in patients with Crohn\u2019s disease and need for parenteral support due to short bowel syndrome-associated intestinal failure. J Clin Gastroenterol. 2016. doi: 10.1097\/MCG.0000000000000604 .","DOI":"10.1097\/MCG.0000000000000604"},{"key":"703_CR38","doi-asserted-by":"crossref","unstructured":"Pevny S, Maasberg S, Karber M, et al. Analysis of treatment results with teduglutide on intestinal absorption and nutritional status in patients with short bowel syndrome [abstract no. P1636]. In: 24th UEG Week; 2016.","DOI":"10.1097\/01.tp.0000521385.24371.f9"},{"issue":"Suppl 1","key":"703_CR39","doi-asserted-by":"crossref","first-page":"S750","DOI":"10.14309\/00000434-201510001-01765","volume":"110","author":"SJ Bowlin","year":"2015","unstructured":"Bowlin SJ, Youssef NN, Kim EH. Design and details of a prospective global short bowel syndrome patient population registry [abstract no. 1765]. Am J Gastroenterol. 2015;110(Suppl 1):S750.","journal-title":"Am J Gastroenterol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0703-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T05:28:35Z","timestamp":1749965315000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,14]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0703-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,14]]}}}